Showing 841-850 of 1226 results for "".
- EyePoint Pharmaceuticals Names Jay S. Duker, MD, Chief Strategic Scientific Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-names-jay-s-duker-md-chief-strategic-scientific-officer/2478005/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-rela
- Johnson & Johnson Vision Appoints Rajesh K. Rajpal, MD, Chief Medical Officerhttps://modernod.com/news/johnson-johnson-vision-appoints-rajesh-k-rajpal-md-chief-medical-officer/2477634/Johnson & Johnson Vision has appointed Rajesh K. Rajpal, MD, as Chief Medical Officer and Global Head of Clinical and Medical Affairs. In this role, Dr. Rajpal will lead the integration of rapidly evolving medical and clinical insights into new product development to address unmet needs of pa
- Iveric Bio Appoints Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officerhttps://modernod.com/news/iveric-bio-appoints-pravin-u-dugel-md-as-executive-vice-president-and-chief-strategy-and-business-officer/2477448/Iveric bio announced the appointment of Pravin U. Dugel, MD, as Executive Vice President and Chief Strategy and Business Officer, effective April 1, 2020. In this role, Dr. Dugel will help shape Iveric bio’s business development strategy going forward. Dr. Dugel brings more than 25 years’ experie
- Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officerhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-david-a-hollander-md-mba-as-chief-research-development-officer/2477056/Aerie Pharmaceuticals announced the appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., PhD, Aerie’s Chairman and Chief Executive Officer. Dr. Hollander will commence his employment at Aerie on Nov
- Nick Mamalis, MD, Named 2019 ASCRS President as ASCRS Unveils New Brandinghttps://modernod.com/news/nick-mamalis-md-named-2019-ascrs-president-as-ascrs-unveils-new-branding/2476560/Nick Mamalis, MD, a well-known ophthalmologist and longtime co-editor of the Journal of Cataract & Refractive Surgery, assumed his role as president of the American Society of Cataract and Refractive Surgery (ASCRS) during the ASCRS meeting’s opening general session here this p
- Thomas Walters, MD, Presents Update on Nicox’s NCX 470 Phase 2 Clinical Study in Podium Presentation at ASCRS 2019https://modernod.com/news/thomas-walters-md-presents-update-on-nicoxs-ncx-470-phase-2-clinical-study-in-podium-presentation-at-ascrs-2019/2476555/Nicox SA announced that ophthalmology key opinion leader and clinical investigator in the ongoing NCX 470 phase 2 clinical study, Thomas Walters, MD, delivered a podium presentation at the annual ASCRS 2019 meeting in San Diego updating on the progress of the NCX 470 phase 2 clinical study in pat
- Bausch + Lomb Highlights Role of B Vitamins in Reducing AMD Risk in New Scientific Reviewhttps://modernod.com/news/bausch-lomb-highlights-role-of-b-vitamins-in-reducing-amd-risk-in-new-scientific-review/2486806/Key Takeaways
- B+L Introduces INFUSE for Astigmatism Silicone Hydrogel Daily Disposable Contact Lenseshttps://modernod.com/news/bausch-lomb-introduces-infuse-for-astigmatism-silicone-hydrogel-daily-disposable-contact-lenses/2482316/Bausch + Lomb has introduced 'INFUSE for Astigmatism' daily disposable contact lenses in the US. Engineered with a next-generation lens material infused with ProBalance Technology and the company’s proprietary OpticAlign design, Bausch + Lomb says INFUSE for
- Pfizer’s COVID-19 Vaccine Stimulates Lower Antibody Response Against B.1.351 Strainhttps://modernod.com/news/pfizers-covid-19-vaccine-stimulates-lower-antibody-response-against-b-1-351-strain/2478888/Preliminary findings from an in vitro study published Wednesday in the NEJM showed that Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 elicited roughly two-thirds lower levels of neutralizing antibodies against a highly transmissible SARS-CoV-2 variant that was first spotted in So
- B+L: Investigational In Vitro Data Indicates Complete Inactivation Of SARS-CoV-2 With Lumify and Besivance Eye Dropshttps://modernod.com/news/bausch-health-announces-investigational-in-vitro-data-indicating-complete-inactivation-of-sars-cov-2-with-lumify-and-besivance-eye-drops/2478558/Bausch Health Companies and Bausch + Lomb announced the results of new investigational in vitro data showing that two benzalkonium chloride (BAK) preserved eye drops, Lumify (brimonidine tartrate ophthalmic solution 0.025%) redness reliever eye drops and Besivance (besifloxacin ophthalmic